Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Status:
Completed
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to
evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate
symptoms of respiratory illness caused by coronavirus 2019 infection.